Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 58
- Registration Number
- NCT00042887
- Locations
- 🇧🇪
Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Gent, Ghent, Belgium
🇧🇪Virga Jesse Hospital, Hasselt, Belgium
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Registration Number
- NCT00024271
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- University College London (UCL) Cancer Institute
- Target Recruit Count
- 600
- Registration Number
- NCT00025090
- Locations
- 🇬🇧
Cancer Research UK and University College London Cancer Trials Centre, London, England, United Kingdom
🇬🇧Northwick Park Hospital, Harrow, England, United Kingdom
🇬🇧Cookridge Hospital, Leeds, England, United Kingdom
Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- British Thoracic Society
- Registration Number
- NCT00030459
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
🇬🇧Leeds Teaching Hospital Trust, Leeds, England, United Kingdom
🇬🇧Princess Royal Hospital, Hull, England, United Kingdom
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 682
- Registration Number
- NCT00003596
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.